Stock Markets September 8, 2026 07:48 AM

Solaris Energy Infrastructure Raises EBITDA Targets, Shares Tick Higher

Company lifts third- and fourth-quarter 2026 Adjusted EBITDA guidance and issues initial outlook for Q1 2027

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
SEI

Solaris Energy Infrastructure (NYSE: SEI) reported raised Adjusted EBITDA guidance for the third and fourth quarters of 2026 and provided an initial projection for the first quarter of 2027. The stock climbed about 6% on the news as the company cited stronger contributions from core power services and better-than-expected results from recently acquired businesses.

Solaris Energy Infrastructure Raises EBITDA Targets, Shares Tick Higher
SEI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Solaris raised third-quarter 2026 Adjusted EBITDA guidance to $110 million - $130 million from $90 million - $105 million, a 23% midpoint increase.
  • Fourth-quarter 2026 Adjusted EBITDA guidance increased to $145 million - $180 million from $100 million - $120 million, a 48% midpoint increase.
  • Company issued initial Adjusted EBITDA guidance for Q1 2027 of $200 million - $240 million; equity market responded with a roughly 6% share price rise.

Shares of Solaris Energy Infrastructure, Inc. (NYSE: SEI) rose about 6% on Tuesday after the company updated its near-term earnings outlook and released a first-quarter 2027 projection.

The company raised its Adjusted EBITDA guidance for both the third and fourth quarters of 2026, citing stronger-than-anticipated contributions from its core power services unit along with improved performance from businesses it acquired recently.

For the third quarter of 2026, Solaris now anticipates Adjusted EBITDA in a range of $110 million to $130 million. That replaces the firm's earlier guidance of $90 million to $105 million and represents a 23% increase at the midpoint of the range.

Guidance for the fourth quarter of 2026 was also increased, with a new range of $145 million to $180 million. The prior fourth-quarter outlook was $100 million to $120 million, yielding a 48% rise at the midpoint versus the previous estimate.

In addition to the revised 2026 quarterly outlooks, Solaris initiated guidance for the first quarter of 2027, projecting Adjusted EBITDA between $200 million and $240 million.


Context and implications

The company attributed the upward revisions to stronger contributions from its core power services business and to better-than-expected results from recently acquired entities. These specific operational drivers were identified by the firm as the reasons behind the improved near-term profitability outlook.

Investors responded to the guidance update with a roughly 6% increase in the company’s share price on the day of the announcement.


What the company disclosed

  • Updated Adjusted EBITDA guidance for Q3 2026: $110 million to $130 million (previously $90 million to $105 million) - a 23% increase at the midpoint.
  • Updated Adjusted EBITDA guidance for Q4 2026: $145 million to $180 million (previously $100 million to $120 million) - a 48% increase at the midpoint.
  • Initial Adjusted EBITDA guidance for Q1 2027: $200 million to $240 million.

This article presents the company's published guidance figures and the market reaction. It does not add forecasts or additional financial metrics beyond those the company provided.

Risks

  • The raised guidance is explicitly linked to stronger contributions from core power services and improved results from recent acquisitions - if those drivers change, future results could differ from the revised outlook.
  • The company provided initial guidance only through the first quarter of 2027, leaving subsequent periods without published forecasts and therefore subject to greater uncertainty.

More from Stock Markets

UBS Highlights Three European Utilities as Sector Leaders Amid Energy Transition Sep 8, 2026 Robinhood Shares Lifted by Dual Analyst Upgrades and Early Blockchain, Prediction-Market Revenue Signals Sep 8, 2026 GameStop heads into earnings with investment gains in focus as core sales slide Sep 8, 2026 ZIM Shares Jump After Acquirors Say They Will Revise $4.2 Billion Offer Sep 8, 2026 BofA Highlights AstraZeneca, Bayer, Roche as Top Pharma Picks; Genmab Stands Out in SMID Biotech Sep 8, 2026